Repare Therapeutics Inc. announced the execution of a Cooperative Research and Development Agreement (CRADA) with the Cancer Therapy Evaluation Program (CTEP) of the US National Cancer Institute (NCI). This partnership aims to advance the development of camonsertib as an anticancer agent.
The collaboration with CTEP will allow the research community to more easily investigate the full clinical potential of camonsertib. This is expected to provide additional clinical development catalysts for the program.
Camonsertib, an oral small molecule ATR inhibitor, has shown significant anti-tumor activity in preclinical and clinical studies. The NCI's CTEP is particularly interested in combination studies involving camonsertib and various aspects of radiation therapy, as well as translational studies to identify predictive biomarkers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.